It was a quiet week for new rulings or warning letters — but two pieces of fresh analysis made clear how much is riding on the decisions still sitting on regulators’ desks. One lays out what actually changes if the Seventh Circuit rules retatrutide a biologic instead of a drug: years of exclusivity, Medicare negotiation timing, and whether compounding is ever legally possible again. The other shows July’s six-peptide compounding vote was only round one, with a second, larger PCAC review already taking shape. Neither is a new decision — both are worth understanding before the real ones land.
What Actually Changes If Retatrutide Is Ruled a Biologic Instead of a Drug
The Seventh Circuit heard oral argument on September 24 in Eli Lilly and Company v. Kennedy, the appeal over whether retatrutide should legally be classified as a “drug” or a “biologic.” There’s still no ruling, which isn’t unusual — appellate decisions like this typically take weeks to months. But an analysis published October 7 by the American Journal of Managed Care spells out what’s at stake once one arrives, and the gap is bigger than most coverage has let on.
The classification decides four things. Market exclusivity runs 12 years for a biologic versus 5 for a drug under a New Drug Application. Medicare negotiation eligibility follows a similar split — roughly year 11 versus year 7, with negotiated prices taking effect around year 13 versus year 9. A drug faces generic competition once exclusivity ends; a biologic faces only slower-moving biosimilars. And compounding is the starkest difference: a drug could eventually become eligible for compounding during a shortage, while a biologic is permanently excluded from compounding exemptions, full stop.
Why It Matters
This is the same case we covered when the Seventh Circuit heard oral argument and when Lilly first took the fight to that court — what’s new is how clearly the trade-offs are now laid out. The classification decided here will shape whether retatrutide ever has a legal compounding pathway at all, which matters more to patients than to Lilly’s balance sheet. Retatrutide remains unapproved and in Phase 3 trials regardless of how the court rules; anything sold under that name outside a clinical trial today is being sold illegally.
The FDA’s Two-Track Peptide Strategy: A Second, Bigger Compounding Vote Is Already Taking Shape
A September 22 legal analysis from Sheppard, Mullin, Richter & Hampton laid out the pattern plainly: the FDA is running two tracks on peptides at once, and neither is slowing down for the other.
Track one is enforcement. On August 24, the agency’s Center for Drug Evaluation and Research sent warning letters to four peptide sellers — Royal Peptides LLC, Peptide Partners LLC, NuScience Peptides LLC, and Peak Performance Peptides — after finding therapeutic marketing claims for products including tirzepatide, semaglutide, retatrutide, and survodutide sold as injectables. The letters rejected “research use only” disclaimers and treated the bacteriostatic water sold alongside the peptides as a drug in its own right.
Track two is the compounding pathway everyone’s been watching since July, when the Pharmacy Compounding Advisory Committee voted to recommend six peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax — for the legal 503A bulk-drug list. What hasn’t been widely reported: a second PCAC meeting is already expected before February 2027, to review a longer list reportedly including LL-37, GHK-Cu, Dihexa, Melanotan II, and two forms of mechano growth factor. Getting any peptide onto the legal list still requires full notice-and-comment rulemaking, which analysts estimate could extend into 2027 or 2028 even for the six already recommended.
Why It Matters
The two tracks explain the tension patients keep running into: an advisory committee can vote yes on a peptide, and the FDA can still treat it as an unapproved drug for years afterward, while enforcement against unauthorized sellers continues in real time. A “committee recommended it” headline is not the same as “legal to buy.”
Where the Compounding Review Stands
No change since last week. The PCAC’s July recommendation for six peptides remains with HHS, with no proposed rule or timeline. A second PCAC meeting is expected before February 2027. The EVEXIAS Life Sciences lawsuit against the FDA over its “Category 2” peptide listing remains unresolved. And the Seventh Circuit has not ruled on retatrutide’s classification since hearing oral argument on September 24, now over two weeks out, consistent with typical appellate timelines.
How to Read “Nothing New This Week” Without Getting Misled
A quiet week in rulings doesn’t mean a quiet week in risk:
- “Still pending” cuts both ways. A peptide recommended for compounding isn’t legal to buy yet. A drug that hasn’t been ruled a biologic isn’t automatically safe to compound either.
- Warning letters lag. The letters published in August describe website reviews from July — enforcement news you read today usually reflects a seller’s status from weeks earlier, not right now.
- A patent case is also an access case. Coverage of the retatrutide fight frames it as a dispute over Lilly’s exclusivity, but the compounding provision is the part that actually affects anyone hoping to access a compounded version someday.
Why This Matters If You’re Considering Peptide Therapy
- Physician-guided only. Every treatment plan is reviewed and prescribed by an independent physician licensed in your state, only when clinically appropriate — not approved by a checkout page.
- Vetted, licensed U.S. pharmacies. We work only with pharmacy partners held to accreditation-level standards, and we track enforcement actions and legal status changes as closely as we track the science.
- Care plans that adapt as regulation changes. Whatever the Seventh Circuit, HHS, or the next PCAC meeting decides, your plan follows what can be legally and safely dispensed at the time — not what a marketing page is selling.
FAQ
Has the Seventh Circuit ruled on retatrutide’s legal classification?
No. The court heard oral argument on September 24, 2026, and has not issued a decision. Appellate rulings like this typically take weeks to months.
What’s different between retatrutide being classified a “drug” versus a “biologic”?
A drug classification brings 5 years of exclusivity, Medicare negotiation around year 7, generic competition once exclusivity ends, and a possible future compounding pathway during shortages. A biologic brings 12 years of exclusivity, Medicare negotiation around year 11, only biosimilar competition, and permanent exclusion from compounding.
Is a second FDA compounding vote really coming?
Legal analysis published in September 2026 says the Pharmacy Compounding Advisory Committee is expected to meet again before February 2027 to review additional peptides beyond the six recommended in July. No date has been formally announced.
Were there new FDA warning letters or recalls this week?
No new ones. The most recent warning letters — to Royal Peptides LLC, Peptide Partners LLC, NuScience Peptides LLC, and Peak Performance Peptides — are dated August 24, 2026.
Is retatrutide legal to buy right now?
No. It remains in Phase 3 trials with no FDA-approved version. Any retatrutide sold online today is being sold illegally, regardless of how the Seventh Circuit rules.
This article is for informational purposes only and does not constitute medical advice. Peptide therapy should only be pursued under the guidance of a licensed physician.
Sources
- AJMC — 5 Things to Know If Retatrutide Is Classified as a Biologic (October 7, 2026)
- American Health Law Association — U.S. Court in Indiana Says FDA Must Reconsider Whether Retatrutide Is a Biologic
- Sheppard Mullin — FDA Balances Peptide Policy With Enforcement Against Unlawful Peptide Sellers (September 22, 2026)
- FDA — Warning Letter to Royal Peptides LLC (August 24, 2026)
- DLA Piper — FDA AdComm Recommends Adding Six Peptides to Bulk List (July 31, 2026)
- Boesen & Snow Law — Retatrutide, Blah, Blah…BLA? (confirming September 24, 2026 Seventh Circuit oral argument date)